Advertisement
News
Advertisement

Zalicus stock plummets 33% after halting Synavive trial

Mon, 09/10/2012 - 12:00am
Mass High Tech: The Journal of New England Technology

The stock of Cambridge biopharmaceutical company Zalicus Inc. took a 33 percent dive on Monday after the company announced it’s stopping trials of Synavive, which it had hoped would improve on drugs now on the market to treat rheumatoid arthritis.

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading